Abstract Details

Title Social Determinants of Health Regarding Hospitalization and Comorbidities in a Nationally Representative Inpatient Sample of Individuals With and Without Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:00 PM-6:00 PM)

Poster/Presentation
Number 18-001

Objective To identify hospitalization trends and comorbidities among patients with Multiple Sclerosis (MS relative to non-MS admissions)

Background

MS is a chronic neuroinflammatory disorder which can require hospitalization for establishing the diagnosis or managing disease related complications.

Design/Methods

Data was leveraged from the Healthcare Cost and Utilization Project (HCUP), a nationally representative US government survey of hospital admissions. MS hospitalization cases were defined by a primary ICD-10 code of ‘G35’. Additional ICD-10 codes listed for a hospitalization (e.g. depression, anxiety, and pain) were analyzed as comorbidities. Demographics (age, race, ethnicity, insurance status) and comorbidities were compared between MS and non-MS admissions.

Results

Between January 2019 and December 2019 there were a total of 25,155 MS admissions and 35,392,578 non-MS admissions. Mean age at admission was 45.9 years for MS versus 50.2 years for non-MS admissions (p < 0.001). MS admissions were 72% female compared to 55.8% (p < 0.001) for non-MS. For MS admissions, 58.3% of patients were White, 26.7% Black, and 10.3% Hispanic compared to non-MS admissions at 64.9%, 15.4%, and 12.4% respectively (p < 0.001). Patients with MS were more likely to have a diagnosis of anxiety (18.9% versus 10.2%, p < 0.001), chronic pain (10.5% versus 5%, p < 0.001), and depression (21.8% versus 9.9%, p < 0.001) compared to non-MS admissions. Among MS admissions, depression diagnoses were reported less often among Black vs. non-Black (16.6% versus 23.6%, p < 0.001), Hispanic vs. Non-Hispanic (13.8% versus 22.7%, p < 0.001), and patients on public vs. commercial insurance (19.1% versus 22.6%, p < 0.001).

Conclusions MS patients have higher rates of anxiety, depression, and pain compared to non-MS patients. Minoritized groups with MS are less likely to be given a secondary diagnosis code for depression, anxiety or pain, possibly reflecting underdiagnosis of these conditions.

Authors/Disclosures
Aneesh Kamath PRESENTER	Mr. Kamath has nothing to disclose.
Lauren B. Krupp, MD, FAAN (NYU Langone Medical Center)	Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care.
Kimberly O'Neill, MD	Dr. O'Neill has nothing to disclose.